PL3104853T3 - Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych - Google Patents

Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych

Info

Publication number
PL3104853T3
PL3104853T3 PL15745862T PL15745862T PL3104853T3 PL 3104853 T3 PL3104853 T3 PL 3104853T3 PL 15745862 T PL15745862 T PL 15745862T PL 15745862 T PL15745862 T PL 15745862T PL 3104853 T3 PL3104853 T3 PL 3104853T3
Authority
PL
Poland
Prior art keywords
treatment
cell stabilizers
systemic disorders
torsion cell
torsion
Prior art date
Application number
PL15745862T
Other languages
English (en)
Inventor
William Gerhart
Manfred Keller
Ahmet Tutuncu
Pravin Soni
Original Assignee
Respivant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Respivant Sciences Gmbh filed Critical Respivant Sciences Gmbh
Publication of PL3104853T3 publication Critical patent/PL3104853T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
    • A61M11/041—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/06—Sprayers or atomisers specially adapted for therapeutic purposes of the injector type
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL15745862T 2014-02-10 2015-02-09 Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych PL3104853T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201461937928P 2014-02-10 2014-02-10
US201461971709P 2014-03-28 2014-03-28
US201461978711P 2014-04-11 2014-04-11
US201562105423P 2015-01-20 2015-01-20
PCT/US2015/015029 WO2015120389A1 (en) 2014-02-10 2015-02-09 Mast cell stabilizers treatment for systemic disorders
EP15745862.1A EP3104853B1 (en) 2014-02-10 2015-02-09 Mast cell stabilizers treatment for systemic disorders

Publications (1)

Publication Number Publication Date
PL3104853T3 true PL3104853T3 (pl) 2020-05-18

Family

ID=53773987

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15745862T PL3104853T3 (pl) 2014-02-10 2015-02-09 Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych

Country Status (13)

Country Link
US (10) US20150224077A1 (pl)
EP (2) EP3104853B1 (pl)
JP (2) JP2017510624A (pl)
CN (1) CN106456595A (pl)
AU (3) AU2015213678C1 (pl)
CA (1) CA2938994A1 (pl)
DK (1) DK3104853T3 (pl)
ES (1) ES2762806T3 (pl)
HU (1) HUE047319T2 (pl)
PL (1) PL3104853T3 (pl)
PT (1) PT3104853T (pl)
SI (1) SI3104853T1 (pl)
WO (1) WO2015120389A1 (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US9855276B2 (en) 2012-10-25 2018-01-02 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CA2938994A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Inhalable formulations of sodium cromolyn with improved bioavailability
CN106535889A (zh) * 2014-02-10 2017-03-22 帕塔拉制药有限责任公司 用于治疗肺疾病的肥大细胞稳定剂
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
KR101694753B1 (ko) * 2015-08-28 2017-01-11 주식회사 온코크로스 크로몰린 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 간질환 예방 및 치료용 약학적 조성물
US20180311236A1 (en) * 2015-10-28 2018-11-01 Ab Science Use of masitinib and other mast cell inhibitors for treatment of parkinson's disease
CN108472393A (zh) * 2015-11-19 2018-08-31 阿尔茨治疗方法公司 用于治疗阿尔茨海默病和有关病症的方法
AU2016359674A1 (en) * 2015-11-23 2018-06-14 The General Hospital Corporation Compositions and methods for treating ischemic stroke
EP3506894B1 (en) 2016-08-31 2023-08-23 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
EP3506893A4 (en) * 2016-08-31 2020-01-22 Respivant Sciences GmbH CROMOLYN COMPOSITIONS FOR THE TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONAL FIBROSIS
JP2019529541A (ja) 2016-09-08 2019-10-17 エマーゴ セラピューティクス，インク． 高サイトカイン血症及びウィルス感染の処置の為の肥満細胞安定剤
AU2017339366A1 (en) 2016-10-07 2019-04-11 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
WO2018075574A1 (en) * 2016-10-18 2018-04-26 Emergo Therapeutics, Inc. Mast cell stabilizers for treatment of chronic inflammatory conditions
CN108619127B (zh) * 2017-03-21 2023-05-26 中国科学院分子细胞科学卓越创新中心 Aldh1a及其激动剂、催化产物和抑制剂的用途
JP7048642B2 (ja) 2017-05-04 2022-04-05 ナノロジカ アクティエボラーグ 肺、鼻、舌下および／または咽頭への送達に適した、少なくとも１つの生物活性化合物をロードした多孔質シリカ粒子の製造方法
WO2019017995A1 (en) 2017-07-20 2019-01-24 Aztherapies, Inc. FORMULATIONS OF CROMOLYNE SODIUM POWDER AND IBUPROFEN
CN108175849B (zh) * 2018-01-15 2021-08-27 吉林省博大伟业制药有限公司 聚普瑞锌口服制剂及在制备溃疡性结肠炎药物中的应用
JP2021529771A (ja) * 2018-07-02 2021-11-04 ザ ジェネラル ホスピタル コーポレイション クロモリンナトリウムおよびα−ラクトースの粉末製剤
US12383528B2 (en) 2018-12-10 2025-08-12 The General Hospital Corporation Cromolyn esters and uses thereof
WO2020234439A1 (en) * 2019-05-22 2020-11-26 Ac Bioscience Sa Composition and use thereof for the treatment of cutaneous mastocytosis
US11278688B2 (en) * 2020-03-12 2022-03-22 Max Azevedo Inhaling device for heavy metal salts and a method of use thereof for medical treatment
JP2023520580A (ja) 2020-04-06 2023-05-17 ザ ジェネラル ホスピタル コーポレイション コロナウイルス誘発炎症状態の処置方法
CN116437903A (zh) * 2020-08-14 2023-07-14 伊斯坦布尔大学 肝素组合物在通过吸入途径通过软雾吸入器或振动网状技术雾化器治疗病毒性肺病、急性和/或慢性肺病中的用途
CA3189623A1 (en) * 2020-09-04 2022-03-10 John Wayne Kennedy Mineral cation complex compositions, formulations therof, and methods of use therof
US20230355517A1 (en) * 2020-09-14 2023-11-09 Atanbul Universitesi Rektolugu Use of active substances with antiviral, anti malarial, and/or mucolytic properties in the treatment of viral lung diseases including covid-19 by soft mist inhaler or vibration mesh technology nebulizer through inhalation route
WO2022146914A1 (en) 2020-12-28 2022-07-07 The General Hospital Corporation Cromolyn derivatives and uses thereof
CN115678300B (zh) * 2021-07-22 2023-11-28 东莞美哲塑胶制品有限公司 壳塑复合材料、其加工方法与应用
WO2025215658A1 (en) * 2024-04-09 2025-10-16 Prabakaran Desomayanandam Pharmaceutical compositions of ketotifen

Family Cites Families (270)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3686412A (en) 1965-03-25 1972-08-22 Colin Fitzmaurice Compositions containing bis-chromonyl compounds for inhibiting antigen-antibody reactions
US3686320A (en) 1965-03-25 1972-08-22 Fisons Pharmaceuticals Ltd Bis-phenoxy compounds
US3777033A (en) 1965-03-25 1973-12-04 Fisons Pharmaceuticals Ltd Bis-chromonyl pharmaceutical composi-tion and methods
GB1144905A (en) 1965-03-25 1969-03-12 Fisons Pharmaceuticals Ltd Substituted bis-(2-carboxy-chromonyl-oxy) derivatives and preparation and pharmaceutical compositions thereof
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3720690A (en) 1970-04-10 1973-03-13 Fisons Pharmaceuticals Ltd Pharmaceutically active bis-carboxychromone compounds
US3683320A (en) 1970-05-08 1972-08-08 Bunker Ramo Coaxial cable connectors
CA958714A (en) 1970-09-03 1974-12-03 Peter B. Johnson Bis-chromone derivatives
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
BE795384A (fr) 1972-02-14 1973-08-13 Ici Ltd Pansements
US4152448A (en) 1972-02-15 1979-05-01 Fisons Limited Method and composition for the treatment of a condition of the gastro intestinal tract
US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
GB1475503A (en) 1973-12-19 1977-06-01 Fisons Ltd Topical compositions
US3993072A (en) 1974-08-28 1976-11-23 Alza Corporation Microporous drug delivery device
US4151273A (en) 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
US3972995A (en) 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US4067992A (en) 1975-09-10 1978-01-10 Fisons Limited Method of treating a psychiatric condition
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4060084A (en) 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4189571A (en) 1978-02-07 1980-02-19 Fisons Limited Esters of cromoglycates
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US4230105A (en) 1978-11-13 1980-10-28 Merck & Co., Inc. Transdermal delivery of drugs
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4268519A (en) 1979-06-05 1981-05-19 Fisons Limited Method of treating otitis media
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
FR2505798B1 (fr) 1981-05-14 1986-07-25 Pari Symac Perfectionnement aux dispositifs comportant un ressort helicoidal utilise comme organe de transfert, d'extraction, de dosage ou de melange
EP0084898B1 (en) 1982-01-22 1986-09-03 FISONS plc Liposome and sodium cromoglycate compositions, and methods for their preparation
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US4996296A (en) 1983-07-27 1991-02-26 Yeda Research & Development Co., Ltd. Cromolyn binding protein in highly purifed form, and methods for the isolation thereof
US4683135A (en) 1983-07-27 1987-07-28 Yeda Research And Development Co., Ltd. DSCG binding protein and process for preparing same
GB8322178D0 (en) 1983-08-17 1983-09-21 Sterwin Ag Preparing aerosol compositions
US4634699A (en) 1983-11-30 1987-01-06 Burroughs Wellcome Co. Branched chain phenothiazine
GB8332450D0 (en) 1983-12-06 1984-01-11 Fisons Plc Method of treatment
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
GB2167300B (en) 1984-11-23 1988-11-23 Fisons Plc Formulations
JPH0662601B2 (ja) 1985-08-16 1994-08-17 京都薬品工業株式会社 クロモグリク酸誘導体および抗アレルギ−剤
GB8520662D0 (en) 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
US4923892A (en) 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5231170A (en) 1986-08-27 1993-07-27 Paul Averback Antibodies to dense microspheres
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
DE3879811T2 (de) 1987-08-25 1993-10-07 Kuebler Gmbh Dr Pharmazeutische Zusammensetzung und ihre Verwendung.
US4906476A (en) 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
EP0413583A3 (en) 1989-08-18 1991-07-17 Dey Laboratories; Inc. Clear, stable cromolyn formulation
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5280784A (en) 1990-09-19 1994-01-25 Paul Ritzau Pari-Werk Gmbh Device in particular and inhalating device for treating the lung and the respiratory tracts
US5753208A (en) 1990-11-09 1998-05-19 Egis Gyogyszergyar Antiasthmatic aerosol preparation of sodium cromoglycate
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
DE122007000103I1 (de) 1990-12-05 2008-04-03 Gen Hospital Corp Verwendung von NO zur Behandlung der persistenten pulmonalen Hypertonie des Neugeborenen
DE59107894D1 (de) 1991-03-21 1996-07-11 Ritzau Pari Werk Gmbh Paul Vernebler insbesondere zur Anwendung in Geräten für die Inhalationstherapie
AU1537292A (en) 1991-04-16 1992-11-17 Nippon Shinyaku Co. Ltd. Method of manufacturing solid dispersion
US6123924A (en) 1991-09-25 2000-09-26 Fisons Plc Pressurized aerosol inhalation compositions
ATE155695T1 (de) 1991-11-07 1997-08-15 Ritzau Pari Werk Gmbh Paul Vernebler insbesondere zur anwendung in geräten für die inhalationstherapie
EP0540774B1 (de) 1991-11-07 1995-05-03 PAUL RITZAU PARI-WERK GmbH Flüssigkeitszerstäubervorrichtung
US5618842A (en) 1991-12-31 1997-04-08 Lifegroup S.P.A. N-acyl derivatives of aminoalcohols with polycarboxylic acids able to modulate mast cells in inflammatory processes having neuroimmunogenic origin
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
GB9214390D0 (en) 1992-07-07 1992-08-19 Fisons Plc Formulations
AU4198793A (en) 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
DE4225928A1 (de) 1992-08-05 1994-02-10 Ritzau Pari Werk Gmbh Paul Zerstäubervorrichtung mit Heizeinrichtung
US5700485A (en) 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
DE4310575C1 (de) 1993-03-31 1994-09-15 Ritzau Pari Werk Gmbh Paul Vorrichtung zum Erzeugen von Aerosolpulsen
GB9317752D0 (en) 1993-08-26 1993-10-13 Fisons Plc New pharmaceutical use
ATE168289T1 (de) 1993-12-17 1998-08-15 Pari Gmbh Zerstäuberdüse
US5508451A (en) 1994-07-07 1996-04-16 Hoechst Celanese Corporation Process for the preparation of dialkali metal cromoglycates
US5665378A (en) 1994-09-30 1997-09-09 Davis; Roosevelt Transdermal therapeutic formulation
US6000394A (en) 1994-10-26 1999-12-14 Paul Rizau Pari-Werk Gmbh Generation of an aerosol of an exact dose
US5552436A (en) 1995-04-03 1996-09-03 Ascent Pharmaceuticals, Inc. Process for treating hemangioma
US5576346A (en) 1995-04-03 1996-11-19 Ascent Pharmaceuticals, Inc. Process for treating uremic pruritus
GB9507768D0 (en) 1995-04-13 1995-05-31 Glaxo Group Ltd Method of apparatus
DE19520622C2 (de) 1995-06-06 2003-05-15 Pari Gmbh Vorrichtung zum Vernebeln von Fluiden
SE9502244D0 (sv) 1995-06-20 1995-06-20 Bioglan Ab A composition and a process for the preparation thereof
GB9513218D0 (en) 1995-06-29 1995-09-06 Fisons Plc Inhalation device and method
US6004949A (en) 1995-12-27 1999-12-21 Showa Yakuhin Kako Co., Ltd. Aqueous composition containing cromoglycic acid
DE19602628C2 (de) 1996-01-25 2000-06-29 Pari Gmbh Vernebler
US6923983B2 (en) 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US5824669A (en) 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
US6225327B1 (en) 1996-04-18 2001-05-01 Alcon Laboratories, Inc. Compounds which inhibit human conjunctival mast cell degranulation for treating ocular allergic-type complications
ES2236832T3 (es) 1997-01-16 2005-07-16 Massachusetts Institute Of Technology Preparacion de particulas para inhalacion.
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
WO1998056381A1 (en) 1997-06-09 1998-12-17 Bridge Pharma, Inc. Compounds with combined antihistaminic and mast cell stabilizing activities, intended for ophthalmic use
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
DE19734022C2 (de) 1997-08-06 2000-06-21 Pari Gmbh Inhalationstherapiegerät mit einem Ventil zur Begrenzung des Inspirationsflusses
US5952353A (en) 1997-09-19 1999-09-14 Auburn University Treating/preventing heart failure via inhibition of mast cell degranulation
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
DE69813853T3 (de) 1997-09-29 2011-05-12 Novartis Ag Perforierte mikroteilchen und deren verwendung
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
US5869090A (en) 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
US6323219B1 (en) 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
GB9810949D0 (en) 1998-05-22 1998-07-22 Hewlett Healthcare Limited Formulation
DE19827228C2 (de) 1998-06-18 2000-07-13 Pari Gmbh Flüssigkeitszerstäubervorrichtung
US6946144B1 (en) 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
ATE283033T1 (de) 1998-07-24 2004-12-15 Jago Res Ag Medizinische aerosolformulierungen
EP1102579B1 (de) 1998-08-04 2003-03-19 Jago Research Ag Medizinische aerosolformulierungen
IL140930A0 (en) 1998-08-07 2002-02-10 Emisphere Tech Inc Compounds and compositions for delivering active agents
GB9824604D0 (en) 1998-11-11 1999-01-06 Hewlett Healthcare Limited Treatment of allergic conditions
US6660715B2 (en) 1998-11-19 2003-12-09 Massachusetts Institute Of Technology Nonaqueous solutions and suspensions of macromolecules for pulmonary delivery
US7074388B2 (en) 1998-12-10 2006-07-11 Kos Life Science, Inc. Water stabilized medicinal aerosol formulation
EP1139746A4 (en) 1998-12-22 2003-09-17 Univ North Carolina CONNECTIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISEASES AND THE ADMINISTRATION OF MEDICINAL SUBSTANCES
JP2002534363A (ja) 1999-01-08 2002-10-15 エミスフェアー・テクノロジーズ・インク ポリマー性デリバリー剤及びデリバリー剤化合物
EP1027886B1 (en) 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
EP1173245B1 (en) 1999-05-03 2004-09-01 Battelle Memorial Institute Compositions for aerosolization and inhalation
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
EP1210069B1 (en) 1999-08-25 2004-12-29 Advanced Inhalation Research, Inc. Large porous particles obtainable by spray-drying and suitable for pulmonary administration
US6586008B1 (en) 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
US7129274B1 (en) 1999-11-05 2006-10-31 Emisphere Technologies Inc. Phenoxy carboxylic acid compounds and compositions for delivering active agents
DE19962110C2 (de) 1999-12-22 2003-06-12 Pari Gmbh Inhalationsvernebler mit einstückigem Ventilelement
US6596261B1 (en) 2000-01-25 2003-07-22 Aeropharm Technology Incorporated Method of administering a medicinal aerosol formulation
US20020009491A1 (en) 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8257744B2 (en) 2000-07-07 2012-09-04 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
RU2318829C2 (ru) 2001-11-14 2008-03-10 Сентокор, Инк. Антитела против il-6, композиции, способы и применение
JP5196701B2 (ja) * 2001-11-29 2013-05-15 エミスフィアー テクノロジーズ インコーポレイテッド クロモリンナトリウムの経口投与用製剤
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US6596284B1 (en) 2002-04-30 2003-07-22 Thomas E. Fleming Treating eczema with a combination of isotonic saline ocean® and nasal mast cell stabilizers
EP1542721A4 (en) 2002-06-14 2007-05-02 Centocor Inc MODIFIED "S" ANTIBODIES
WO2004003147A2 (en) 2002-06-27 2004-01-08 Centocor, Inc. Cngh0004 polypeptides, antibodies, compositions, methods and uses
AU2003247641A1 (en) 2002-06-27 2004-01-19 Centocor, Inc. Cngh0005 polypeptides, antibodies, compositions, methods and uses
WO2004023984A2 (en) 2002-09-13 2004-03-25 Smith C Steven Novel composition and method for treatment of upper respiratory conditions
US7550133B2 (en) 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
SE0203687D0 (sv) 2002-12-13 2002-12-13 Ian Harwigsson Med Adagit Fa Pharmaceutical Porous Particles
EP1613657A2 (en) 2003-03-28 2006-01-11 Centocor, Inc. Anti-amyloid antibodies, compositions, methods and uses
JP2007526208A (ja) 2003-04-11 2007-09-13 メディミューン，インコーポレーテッド 呼吸器の症状を治療又は予防する方法
JP2007515939A (ja) 2003-05-09 2007-06-21 セントカー・インコーポレーテツド ＩＬ−２３ｐ４０特異的免疫グロブリン由来タンパク質、組成物、方法および用途
US20050033029A1 (en) 2003-06-30 2005-02-10 Jin Lu Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
US20050026880A1 (en) 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease
DE10347994A1 (de) * 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
US20050209141A1 (en) 2003-10-17 2005-09-22 Silver Randi B Mast cell-derived renin
CA2544924A1 (en) 2003-11-05 2005-05-19 Centocor, Inc. Methods and compositions for treating mcp-1 related pathologies
US20060078558A1 (en) 2003-11-12 2006-04-13 Whitsett Jeffrey A Diagnosis, prognosis and treatment of pulmonary diseases
DE10355559A1 (de) 2003-11-21 2005-06-23 Orthogen Ag Transskin
US20050191246A1 (en) 2003-12-13 2005-09-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powders comprising low molecular dextran and methods of producing those powders
US8088935B2 (en) 2003-12-23 2012-01-03 Ironwood Pharmaceuticals, Inc. Compounds and methods for the treatment of asthma
IL160936A0 (en) 2004-02-05 2004-08-31 Scott A Cordray Nasal spray and wash
WO2005091853A2 (en) 2004-02-27 2005-10-06 Centocor, Inc. Methods and compositions for treating il-13 related pathologies
CA2566161C (en) 2004-05-14 2013-10-01 Emisphere Technologies, Inc. Aryl ketone compounds and compositions for delivering active agents
WO2005115468A1 (ja) 2004-05-26 2005-12-08 Reverse Proteomics Research Institute Co., Ltd. 新規創薬ターゲットならびにこれに作用する医薬
US20060069124A1 (en) 2004-09-07 2006-03-30 Rao P S Use of MDL-100,907 for treatment of allergic and eosinophil mediated diseases
EP1799260A4 (en) 2004-09-29 2011-09-28 Centocor Inc ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, TECHNIQUES AND USES
CN103462894A (zh) 2005-03-16 2013-12-25 霍尼韦尔国际公司 药物递送制剂、装置和方法
WO2006105538A2 (en) 2005-03-31 2006-10-05 Centocor, Inc. Methods and compositions for treating il-21 related pathologies
EP1712220A1 (en) 2005-04-15 2006-10-18 PARI GmbH Spezialisten für effektive Inhalation Pharmaceutical aerosol composition
AU2012238334A1 (en) 2005-06-30 2012-11-01 Abbvie Inc. IL-12/p40 binding proteins
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
GB0520794D0 (en) 2005-10-12 2005-11-23 Innovata Biomed Ltd Inhaler
US7566743B2 (en) 2005-11-18 2009-07-28 Mark Glazman System and method for medical treatment
DK1962869T3 (da) 2005-12-21 2013-06-24 Solaeromed Inc Behandling af luftvejssygdomme
RS55963B1 (sr) 2005-12-29 2017-09-29 Janssen Biotech Inc Humana anti-il-23 antitela, kompozicije, metode i upotrebe
DE102006001113B3 (de) 2006-01-09 2007-06-28 Pari GmbH Spezialisten für effektive Inhalation Aerosoltherapievorrichtung
US8263645B2 (en) * 2006-02-03 2012-09-11 Pari Pharma Gmbh Disodium cromoglycate compositions and methods for administering same
JP2009526003A (ja) * 2006-02-10 2009-07-16 パーリ・ファルマ・ゲーエムベーハー 吸入療法用噴霧状抗生物質
WO2007103970A2 (en) 2006-03-07 2007-09-13 Endacea, Inc. Compositions and methods for treating respiratory disorders
US20080035141A1 (en) 2006-06-16 2008-02-14 Warner W R Aerosolized therapy kit
EP2043687A4 (en) 2006-06-29 2010-03-17 Centocor Ortho Biotech Inc ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, METHODS AND USES
US8445437B2 (en) 2006-07-27 2013-05-21 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers
PL3339445T3 (pl) 2006-09-08 2020-12-14 Abbvie Bahamas Ltd. Białka wiążące interleukinę 13
US20080078382A1 (en) 2006-09-20 2008-04-03 Lemahieu Edward Methods and Systems of Delivering Medication Via Inhalation
GB0621707D0 (en) 2006-10-31 2006-12-13 Univ London Pharmacy Formulations for delivery via pressurised metered dose inhalers
US20100144646A1 (en) 2006-11-03 2010-06-10 Blake Paterson Method of diagnosing and treating asthma
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US20080227704A1 (en) 2006-12-21 2008-09-18 Kamens Joanne S CXCL13 binding proteins
BRPI0807285A2 (pt) 2007-02-08 2014-05-06 Emisphere Tech Inc "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto"
US8252807B2 (en) 2007-03-02 2012-08-28 Board Of Regents, The University Of Texas System Methods of inhibiting the interaction between S100 and the receptor for advanced glycation end-products
US20080214491A1 (en) 2007-03-02 2008-09-04 Logsdon Craig D Methods of Inhibiting the Interaction Between S100 and the Receptor for Advanced Glycation End-Products
WO2008116165A2 (en) 2007-03-21 2008-09-25 Next Safety, Inc. Methods and systems of delivering medication via inhalation
WO2008130718A1 (en) 2007-04-23 2008-10-30 Atherogenics, Inc. Sulfonamide containing compounds for treatment of inflammatory disorders
EP2030644A1 (en) * 2007-08-31 2009-03-04 PARI Pharma GmbH Aerosols for sinunasal drug delivery
JP5460600B2 (ja) 2007-09-28 2014-04-02 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 肥満症治療における肥満細胞安定化薬
JP2011500059A (ja) 2007-10-15 2011-01-06 セントコア・オーソ・バイオテツク・インコーポレーテツド ヒト抗アミロイド抗体、組成物、方法及び使用
DE102007052380A1 (de) 2007-10-31 2009-05-07 Bitop Ag Osmolythaltige Zubereitungen zur Anwendung bei trockenen Schleimhäuten
JP5571561B2 (ja) * 2007-11-06 2014-08-13 スリーエム イノベイティブ プロパティズ カンパニー 医薬品吸入装置及びそれらの構成要素
CN101939040B (zh) 2007-12-20 2014-11-05 阿斯利康(瑞典)有限公司 解聚集粉末的装置和方法
WO2009103067A2 (en) 2008-02-14 2009-08-20 The Children's Hospital Of Philadelphia Compositions and methods to treat asthma
US9095621B2 (en) 2008-04-25 2015-08-04 Nektar Therapeutics Oligome-bis-chromonyl compound conjugates
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
EP3002299A1 (en) 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
PE20100054A1 (es) 2008-06-03 2010-03-03 Abbott Lab Inmunoglobulina con dominio variable dual
US10517839B2 (en) 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
RU2559525C2 (ru) 2008-07-08 2015-08-10 Эббви Инк Белки, связывающие простагландин е2, и их применение
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
US20100087455A1 (en) 2008-10-06 2010-04-08 Auspex Pharmaceuticals, Inc. Substituted xanthine compounds
US20110195924A1 (en) 2008-10-08 2011-08-11 Logsdon Craig D Methods of Inhibiting the Interaction Between S100P and the Receptor for Advanced Glycation End-Products
US20110224312A1 (en) 2008-11-17 2011-09-15 Wayne State University Engineering porous particles of water soluble therapeutics for pressurized metered-dose inhaler formulations
US20100233079A1 (en) 2008-12-04 2010-09-16 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CA2751125C (en) 2009-01-29 2017-06-20 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CN102369217A (zh) 2009-01-29 2012-03-07 雅培制药有限公司 Il-1结合蛋白
TW201613969A (en) 2009-03-05 2016-04-16 Abbvie Inc IL-17 binding proteins
US8470805B2 (en) 2009-04-30 2013-06-25 Kaohsiung Medical University Processes for preparing piperazinium salts of KMUP and use thereof
CN102459347A (zh) 2009-05-01 2012-05-16 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途
ES2457442T3 (es) * 2009-05-08 2014-04-25 Pari Pharma Gmbh Formulaciones farmacéuticas concentradas estabilizadoras de los mastocitos
KR20100129156A (ko) * 2009-05-28 2010-12-08 엘지전자 주식회사 세탁장치
TW201109438A (en) 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AR078254A1 (es) 2009-09-01 2011-10-26 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
MX2012004415A (es) 2009-10-15 2012-05-08 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
TW201124427A (en) 2009-10-15 2011-07-16 Abbott Lab IL-1 binding proteins
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
TR201000733A2 (tr) 2010-02-02 2011-08-22 Bi̇lgi̇ç Mahmut Flutikazon, tiotropyum ve sodyum kromoglikat içeren farmasötik bileşimler.
AU2015200579A1 (en) 2010-04-07 2015-02-26 Abbvie Inc. TNF-alpha binding proteins
PH12012501991A1 (en) 2010-04-07 2017-07-26 Abbvie Inc Tnf-alpha binding proteins
AU2016222339B2 (en) 2010-05-14 2017-11-23 Abbvie Inc. IL-1 binding proteins
AU2011252883B2 (en) 2010-05-14 2015-09-10 Abbvie Inc. IL-1 binding proteins
US8586044B2 (en) 2010-05-28 2013-11-19 Northwestern University Treatment of chronic pelvic pain syndrome
US9592220B2 (en) 2010-06-17 2017-03-14 Aradigm Corporation Diagnosis and treatment methods for entry of gastrointestinal contents into respiratory tract
CN103118726B (zh) 2010-07-21 2015-07-22 阿斯利康(瑞典)有限公司 吸入器
PH12013500337A1 (en) 2010-08-26 2017-08-23 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
JP2014500712A (ja) 2010-11-02 2014-01-16 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
WO2012121775A2 (en) 2010-12-21 2012-09-13 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
TW201307388A (zh) 2010-12-21 2013-02-16 Abbott Lab Ｉｌ－１結合蛋白
UY33827A (es) 2010-12-22 2012-07-31 Abbott Lab Proteínas de unión a media-inmunoglobulina y sus usos
WO2012092594A2 (en) 2010-12-30 2012-07-05 Harish Ziv M D Preparations for topical prevention and/or treatment of oral allergic symptoms due to oral contact with fruits and/or vegetables
GB201110058D0 (en) 2011-06-15 2011-07-27 3M Innovative Properties Co Medicinal inhalation devices, valves and components thereof
KR20140069091A (ko) 2011-09-06 2014-06-09 베로나 파마 피엘씨 기침 및 기침으로 인한 발작 치료
WO2013101993A2 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY34556A (es) 2011-12-30 2013-07-31 Abbvie Inc Dominio variable dual de inmunoglobulinas y sus usos
ES2969344T3 (es) 2012-01-18 2024-05-17 Techfields Pharma Co Ltd Composiciones de profármaco de alta penetración y composición farmacéutica del mismo para el tratamiento de afecciones pulmonares
GB2498746A (en) 2012-01-26 2013-07-31 Innovata Biomed Ltd Inhaler which locks when empty
WO2013128283A2 (en) 2012-02-28 2013-09-06 Iceutica Holdings Inc. Bvi Inhalable pharmaceutical compositions
US20150018396A1 (en) 2012-03-08 2015-01-15 President And Fellows Of Harvard College Prevention and treatment of respiratory infection with peroxisome proliferator activator receptor delta agonist
SG11201406142XA (en) 2012-03-27 2014-10-30 Univ Duke Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage
WO2013169473A1 (en) 2012-05-09 2013-11-14 Virginia Commonwealth University Dry powder inhaler (dpi) designs for producing aerosols with high fine particle fractions
EP2854781A4 (en) 2012-05-25 2016-04-13 Xlear Inc XYLITOL-BASED ANTIMUKOSAL COMPOSITIONS AND ASSOCIATED METHODS AND COMPOSITIONS
US9427534B2 (en) 2012-07-05 2016-08-30 Clement Clarke International Ltd. Drug delivery inhaler devices
TW201402608A (zh) 2012-07-12 2014-01-16 Abbvie Inc Ｉｌ－１結合蛋白質
IL312711A (en) 2012-08-21 2024-07-01 Regeneron Pharma Methods for the treatment or prevention of asthma through the administration of an antagonist to 4R-IL
US9855276B2 (en) 2012-10-25 2018-01-02 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
JP2015537025A (ja) 2012-11-16 2015-12-24 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 音響混合技術を使用して集塊物を作製するためのプロセス
WO2014115098A1 (en) 2013-01-26 2014-07-31 Mahesh Kandula Compositions and methods for the treatment of neurological diseases and inflammation
MX2015013170A (es) 2013-03-15 2016-07-26 Abbvie Inc Proteinas de union especificas duales dirigidas contra tnf alpha.
WO2015002703A1 (en) 2013-05-23 2015-01-08 Aztherapies, Inc Methods for delivering cromolyn
CR20160093A (es) 2013-08-23 2016-08-26 Afferent Pharmaceuticals Inc Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub aguda o cronica
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US9492408B2 (en) 2013-10-24 2016-11-15 University of Pittsburgh—of the Commonwealth System of Higher Education Protection from chemical-induced acute lung injury
GB2522727B (en) 2013-11-26 2017-01-25 Purity Health Pharma Ltd Pulmonary delivery devices
EP2883564A1 (en) 2013-12-16 2015-06-17 PARI Pharma GmbH Aerosol delivery device and method of operating the aerosol delivery device
WO2015120138A2 (en) 2014-02-05 2015-08-13 Dana-Farber Cancer Institute, Inc. AGENTS THAT MODULATE RGMb-NEOGENIN-BMP SIGNALING AND METHODS OF USE THEREOF
CN106535889A (zh) 2014-02-10 2017-03-22 帕塔拉制药有限责任公司 用于治疗肺疾病的肥大细胞稳定剂
CA2938994A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Inhalable formulations of sodium cromolyn with improved bioavailability
US20150273119A1 (en) 2014-03-26 2015-10-01 Snu R&Db Foundation Formulation comprising anti-scarring agents and biocompatible polymers for medical device coating
US20150306107A1 (en) 2014-04-24 2015-10-29 Jansfat Biotechnology Co., Ltd. SAA Derivative Compound Restores eNOS And Inhibits Oxidative Stress-Induced A Diseases In Hypoxia
WO2015161510A1 (en) 2014-04-25 2015-10-29 Jansfat Biotechnology Co., Ltd. Saa derivative compound restores enos and inhibits oxidative stress-induced diseases in hypoxia
US20150337315A1 (en) 2014-05-20 2015-11-26 Michael M. Grunstein Compositions and methods targeting signaling by the g protein beta-gamma subunit for the treatment of asthma
DE102014009164A1 (de) 2014-06-03 2015-12-03 Herbalist & Doc Gesundheitsgesellschaft Mbh Silikonölhaltige nasal anzuwendende Formulierungen
JP6755240B2 (ja) 2014-06-05 2020-09-16 トランスゲニオン−インターナショナル インスティテュート フォー リジェネレイティヴ トランスレイショナル メディシン ゲーエムベーハー 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法
WO2015185656A1 (en) 2014-06-05 2015-12-10 Medizinische Universität Wien Methods of diagnosing chronic obstructive pulmonary disease (copd) using novel molecular biomarkers
WO2015185658A2 (en) 2014-06-05 2015-12-10 Medizinische Universität Wien Methods of diagnosing chronic obstructive pulmonary disease (copd) using novel molecular biomarkers
US20170218091A1 (en) 2014-07-03 2017-08-03 Abbvie Inc. Monovalent binding proteins
WO2016011254A1 (en) 2014-07-16 2016-01-21 Henry J. Legere Md, Pa Combinations of antihistamines and leukotriene antagonists and methods of use thereof
CN106715386B (zh) 2014-09-30 2018-09-25 株式会社Lg化学 (甲基)丙烯酸酯化合物以及包含衍生自其的重复单元的共聚物和均聚物
US20170235918A1 (en) 2014-10-25 2017-08-17 Sumner Bluffs, Llc. Systems and methods for determining compliance and efficacy of a dosing regimen for a pharmaceutical agent
WO2017011729A1 (en) 2015-07-16 2017-01-19 Patara Pharma, LLC Combination therapies for the treatment of lung diseases
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
US20190046444A1 (en) 2015-09-14 2019-02-14 Vgsk Techologies, Inc. A sterically stabilized carrier for subcutaneous, sublingual, and oral therapeutics, compositions and methods for treating a mammal

Also Published As

Publication number Publication date
US9962363B2 (en) 2018-05-08
ES2762806T3 (es) 2020-05-25
EP3104853A4 (en) 2017-08-16
CA2938994A1 (en) 2015-08-13
CN106456595A (zh) 2017-02-22
US20180271828A1 (en) 2018-09-27
US9707206B2 (en) 2017-07-18
US20150224077A1 (en) 2015-08-13
US10398673B2 (en) 2019-09-03
US20150297557A1 (en) 2015-10-22
US20170273941A1 (en) 2017-09-28
WO2015120389A1 (en) 2015-08-13
JP2017510624A (ja) 2017-04-13
US20160367519A1 (en) 2016-12-22
US20180280341A1 (en) 2018-10-04
AU2018200429A1 (en) 2018-02-08
AU2018200429B2 (en) 2019-10-10
US9265749B2 (en) 2016-02-23
US20190175546A1 (en) 2019-06-13
AU2015213678A1 (en) 2016-08-25
SI3104853T1 (sl) 2020-03-31
AU2015213678C1 (en) 2019-03-21
AU2019236630A1 (en) 2019-10-17
PT3104853T (pt) 2020-01-14
AU2015213678B2 (en) 2017-10-19
US20190388386A1 (en) 2019-12-26
US20160346245A1 (en) 2016-12-01
EP3104853A1 (en) 2016-12-21
EP3653207A1 (en) 2020-05-20
US10238628B2 (en) 2019-03-26
US9968586B2 (en) 2018-05-15
EP3104853B1 (en) 2019-10-02
US20190307721A1 (en) 2019-10-10
HUE047319T2 (hu) 2020-04-28
DK3104853T3 (da) 2019-12-09
JP2019116503A (ja) 2019-07-18

Similar Documents

Publication Publication Date Title
SI3104853T1 (sl) Zdravljenje s stabilizatorji mastocitov za sistemske motnje
SI3104854T1 (sl) Stabilizatorji mastocitov za zdravljenje pljučnih bolezni
DK3237442T3 (da) Celle
HUE040315T2 (hu) Beültethetõ elektróda elrendezés
PL2923646T3 (pl) Weryfikacje liczby wymian baterii/liczby zabiegów
DK3267960T3 (da) Stimulationsindretning med forlængelse
HUE055369T2 (hu) Gyógyászati készítmények cisztás fibrózis transzmembrán konduktancia regulátor kövzetítette betegségek kezelésére
PL3492632T4 (pl) Sposoby traktowania materiałów zawierających lit
DK3262066T4 (da) Genterapi
IL243044A0 (en) Far field-insensitive intracardiac catheter electrodes
EP3037812C0 (en) ENZYME ELECTRODE
EP3488484A4 (en) Electrode assemblies
IL242971B (en) Ventricular far field reduction
EP3458307A4 (en) FLUID CHARGE STABILIZER
PT3353336T (pt) Elétrodo
DK3158057T3 (da) Stamcelleterapi ved endometriepatologier
HUE053000T2 (hu) Eljárás stabilizátorok elõállítására
IL254825A0 (en) Methods of treatment with taselisib
DK3212495T3 (da) Flydende struktur
IL237705B (en) Placement of electrodes in proximity to the heart
IL251720B (en) Catheter with shunting electrode
EP3141244C0 (en) EMULSIONS COMPRISING SILICIC ACID
PL3131549T3 (pl) Sposób leczenia zaburzeń ruchowych przy użyciu befiradolu
HRP20181756T1 (hr) Režim liječenja sa spojem tiakumicina
TH1601001268A (th) แท่งสำหรับแรงบิดและวิธีการสำหรับการผลิตของสิ่งนี้